In preclinical models, UCART123 demonstrated significant activity against BPDCN using cells directly from patients, although challenges such as antigenic shift or CD123 loss could limit its effectiveness in clinical settings [53]. This evidence concerns the gene IL3RA and CD4+/CD56+ hematodermic neoplasm.